| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9632660c8c68643eb9846ab851d41eb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K1-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-865 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02 |
| filingDate |
2010-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b3af7e810a980ffd6a086b2f0c62257e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbb96890683ed3dfa71f1c59d8e77694
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfb5d045e2aa3c8fe10e559ab71d7e97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7e2f6f26de7b0565f103ef600042c8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe92843f710bf783b663903afd75938b |
| publicationDate |
2017-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-106986933-A |
| titleOfInvention |
Albumin variants and conjugates |
| abstract |
The present invention relates to albumin variants and conjugates. Based on the three-dimensional structure of albumin, the inventors designed a variant polypeptide (mutein) having one or more cysteine residues with a free sulfhydryl group (hereinafter referred to as "thioalbumin"). The variant polypeptide can be conjugated to a conjugation partner, such as a biologically active compound, through the sulfur atom of the cysteine residue. |
| priorityDate |
2009-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |